Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Vedana Therapeutics | 2026 | Series A | Undisclosed | Seattle |
| Autoimmunity BioSolutions | 2026 | Seed | $2.0M | Houston |
| CREATE Medicines | 2026 | Series B | Undisclosed | Cambridge |
| Kytopen | 2026 | Series B | Undisclosed | Cambridge |
| Fathom Therapeutics | 2026 | Series A | $31.1M | New York |
| Neomorph | 2026 | Series B | Undisclosed | San Diego |
| Tr1x | 2025 | Venture - Series Unknown | $50.0M | San Diego |
| AeroRx Therapeutics | 2025 | Series A | $21.0M | La Jolla |
| Dualitas Therapeutics | 2025 | Series A | $65.0M | San Francisco |
| Leal Therapeutics | 2025 | Series A | $30.0M | Worcester |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Vedana Therapeutics | Series A | Undisclosed | Seattle, United States |
| 2 | Autoimmunity BioSolutions | Seed | $2.0M | Houston, United States |
| 3 | CREATE Medicines | Series B | Undisclosed | Cambridge, United States |
| 4 | Kytopen | Series B | Undisclosed | Cambridge, United States |
| 5 | Fathom Therapeutics | Series A | $31.1M | New York, United States |
| 6 | Neomorph | Series B | Undisclosed | San Diego, United States |
| 7 | Tr1x | Venture - Series Unknown | $50.0M | San Diego, United States |
| 8 | AeroRx Therapeutics | Series A | $21.0M | La Jolla, United States |
| 9 | Dualitas Therapeutics | Series A | $65.0M | San Francisco, United States |
| 10 | Leal Therapeutics | Series A | $30.0M | Worcester, United States |
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
Autoimmunity BioSolutions develops a future immuno-corrective treatment that restores healthy immune function.
CREATE Medicines is a biotech company developing in vivo CAR therapies using mRNA-LNP immune cell programming technology.
Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing.
Fathom Therapeutics focuses on drug design by harnessing biomolecular motion to develop therapeutics that can reprogram protein function.
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments.
Tr1x is a biotechnology company developing novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.
AeroRx Therapeutics is a biopharmaceutical company that developing proprietary, combination products.
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
Leal Therapeutics develops novel therapeutics for patients.
GeneCentric Therapeutics develops and commercializes molecular diagnostic tests for oncologists and patients.
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Hoofprint Biome is a biotechnology company that develops probiotics that improve the sustainability of ruminant livestock production.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the world's most lethal diseases.
Pleno is a biotechnology company that aims speeding up disease diagnosis and treatment.
Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.
TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.
CrossBridge Bio operates as a biotechnology company.
Archon is a biotechnology firm that promotes next-generation antibody treatments through AI and computational protein design.
Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs).
5Metis is a new pure-play discovery company for crop health.
Early stage biotechnology company
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience.
Alexandria Venture Investments has invested in 124 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 19 different industry categories.
Among tracked funding rounds, TRex Bio received $84.0M in a Series B round. Alexandria Venture Investments's total known invested capital is $3.8B.
Alexandria Venture Investments's average investment size is $37.7M across its portfolio of 124 companies.
Recent Alexandria Venture Investments portfolio additions include Vedana Therapeutics, Autoimmunity BioSolutions, CREATE Medicines, Kytopen, Fathom Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors